Showing 9121-9130 of 21415 results for "".
The First Approved All-Oral, Fixed Duration Treatment for CLL: Insights from the AMPLIFY Trial
https://reachmd.com/programs/project-oncology/the-first-approved-all-oral-fixed-duration-treatment-for-cll-insights-from-the-amplify-trial/56747/The treatment landscape for first-line chronic lymphocytic leukemia (CLL) has evolved, with targeted therapies and fixed-duration approaches entering the conversation.1 With venetoclax/acalabrutinib, we have an all-oral, fixed-duration treatment option that doesn’t require infusions.2 The Phase 3 AMMaking the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
https://reachmd.com/programs/cme/Making-the-Right-Moves-in-Metastatic-CSPC-Intensification-Imaging-and-Impact/56687/Experts discuss ADT intensification strategies, trial evidence, and patient selection for doublet and triplet therapy in metastatic CSPC.Management Approaches in Radiographically Isolated Syndrome
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/management-approaches-in-radiographically-isolated-syndrome/32089/How best to define radiographically isolated syndrome has been the subject of debate; challenges in determining the best management approach remain.The Clinical Significance of Imaging in the Management of ADPKD
https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12675/When managing patients with autosomal dominant polycystic kidney disease, what role does radiological imaging play?Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
https://reachmd.com/programs/cme/inside-the-4-hits-targeting-april-to-change-the-course-of-igan/48815/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Improving Preventive Care of Patients With Hepatic Encephalopathy: Navigating the Subtleties and Beyond
https://reachmd.com/programs/cme/improving-preventive-care-of-patients-with-hepatic-encephalopathy-navigating-the-subtleties-and-beyond/36305/Learn how PCPs can identify early signs of hepatic encephalopathy to support timely diagnosis and clinical management.Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
https://reachmd.com/programs/cme/transformative-insights-latest-evidence-for-b7-h3-adcs-from-wclc-and-esmo-2025/36238/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
https://reachmd.com/programs/cme/current-and-emerging-roles-of-immunotherapy-and-adcs-for-patients-with-non-muscle-invasive-and-muscle-invasive-bladder-cancer/14553/Are you applying the latest data to your practice? Tune in for expert guidance on using ADCs and immunotherapy to treat your patients with mUC.Improving Outcomes in PSVT: Best Practices for Choosing Optimal Management Strategies
https://reachmd.com/programs/cme/improving-outcomes-in-psvt-best-practices-for-choosing-optimal-management-strategies/57224/Are you optimally managing your patients with PSVT? Our experts offer best practices and guideline recommendations to improve outcomes in the real world.CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
https://reachmd.com/programs/cme/celmods-in-multiple-myeloma-optimizing-rrmm-treatment-with-potent-immunomodulatory-drugs/54459/This program will equip clinicians with a practical understanding of RRMM diagnosis and risk stratification while building familiarity with CELMoDs as an emerging treatment class with the potential to improve outcomes in relapsed/refractory multiple myeloma. Participants will be educated on the high